A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Trial Details
- NCT ID
- NCT06638307
- Phase
- PHASE1
- Sponsor
- Stemline Therapeutics, Inc.
- Status
- RECRUITING
- Cancer Type
- Breast Cancer
- Interventions
- Locations (sample)
- Springdale, Arkansas, United States|36.18674,-94.12881
- Duarte, California, United States|34.13945,-117.97729
- La Jolla, California, United States|32.84727,-117.2742
- Palo Alto, California, United States|37.44188,-122.14302
- San Francisco, California, United States|37.77493,-122.41942
Key Eligibility Criteria
- Participant has advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy.
- Presence of genetic alterations in PIK3CA/AKT1/PTEN in participants' tumor tissue.
- Participant must have received at least 1 prior line of endocrine therapy for advanced/metastatic disease or participant who has radiological evide…
- Progression on previous cyclin-dependent kinase 4 and 6 inhibitor treatment in combination with fulvestrant or aromatase inhibitor is required.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Breast Cancer Trials on Trialify →